Stocks · News reference
Longeveron Announces Phase 2b ELPIS II Trial Of Laromestrocel In Hypoplastic Left Heart Syndrome Misses Primary Efficacy Endpoint; Initiates Cost-Optimization Measures To Maximize Shareholder Value
The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular ejection fraction (RVEF) at month 12, but there were exploratory clinical endpoints that the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial
Longeveron reported updated results from its ELPIS II Phase 2b clinical trial for laromestrocel in infants with hypoplastic left heart syndrome (HLHS), noting that while the primary endpoint was not met, the therapy showed significant results in reducing major adverse cardiac events.
8-K filing — Longeveron Inc. (LGVN)
Filed: 2026-10-26 AccNo: 0001213900-26-112508 Size: 265 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Longeveron Announces Its ELPIS II Study Of Laromestrocel Failed To Meet Primary Efficacy Endpoint Of Change From Baseline In Right Ventricular Ejection Fraction To Treat Infants With Hypoplastic Left Heart Syndrome